Comparison of Salbutamol Alone and Salbutamol in Combination with Ipratropium Bromide in The Treatment of Acute Asthma in Children
DOI:
https://doi.org/10.36283/ziun-pjmd14-3/030Keywords:
Asthma, Salbutamol, Pulmonary Asthma , Ipratropium BromideAbstract
Background: Acute attacks of childhood bronchial asthma can be life-threatening if not timely and appropriately managed. This study aimed to compare the mean pulmonary asthma score in salbutamol alone versus salbutamol combined with ipratropium bromide for managing childhood acute asthma.
Methods: This single-blind, parallel-group, randomized controlled trial was performed at the Pediatric Medicine department, The Children’s Hospital & the Institute of Child Health, Multan, from January 1, 2024, to June 30, 2024. A total of sixty children of 2–15 years with an acute asthma episode were consecutively enrolled after parental consent. Exclusions included congenital pulmonary/cardiac malformations, bronchopulmonary dysplasia, cystic fibrosis, bronchiolitis obliterans, and imminent respiratory failure. Patients were randomly divided into group A and group B treatment groups. Group A received nebulization of 0.5% salbutamol alone, while Group B received salbutamol with ipratropium bromide. Pulmonary Asthma Score (PAS) was assessed on presentation and after 4 hours. Descriptive statistics are run using SPSS. PAS after 4 hours of treatment between the groups was compared through a t-test, and a p-value <0.05 was taken as significant.
Results: The mean age was 8.6 ± 2.8 years with equal gender distribution. Baseline PAS was comparable (10.2 ± 1.2 vs 10.6 ± 1.2, p = 0.295). After 4 hours, overall PAS declined to 7.4 ± 1.6, with significantly lower scores in the combination group (6.3 ± 1.2) versus salbutamol alone (8.4 ± 1.2, p < 0.001). Stratified analysis confirmed these results except among children on montelukast (p = 0.846).
Conclusion: Nebulization with salbutamol plus ipratropium bromide significantly reduces PAS at 4 hours compared to salbutamol alone in acute pediatric asthma.
References
1. Caminati M, Morais Almeida M, Bleecker E, Ansotegui I, Canonica GW, Bovo C, et al. Biologics and global burden of asthma: a worldwide portrait and a call for action. World Allergy Organ J. 2021 Apr;14(2):100502. doi:10.1016/j.waojou.2020.100502.
2. Craig S, Powell CV, Nixon GM, Oakley E, Hort J, Armstrong DS, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. BMJ Open Respir Res. 2022;9(1):e001137. (Month not specified)
3. Rogerson CM, Hogan AH, Waldo B, White BR, Carroll CL, Shein SL. Wide institutional variability in the treatment of pediatric critical asthma: a multicenter retrospective study. Pediatr Crit Care Med. 2024 Jan;25(1):37 46. doi:10.1097/PCC.0000000000003347.
4. Akashanand, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M, et al. Patterns and trends in burden of asthma and its attributable risk factors from 1990 to 2021 among South Asian countries: a systematic analysis for the Global Burden of Disease Study 2021. J Asthma. 2025 Jan;62(6): 1020 1031. doi:10.1080/02770903.2025.2453810 .
5. Sio YY, Chew FT. Risk factors of asthma in the Asian population: a systematic review and meta analysis. J Physiol Anthropol. 2021;40(1):22. doi:10.1186/s40101 021 00273 x.
6. Samoo UG, Ehsan S. Prevalence of asthma and allergic disorders in school children of Karachi. Int J Contemp Pediatr. 2021 Nov;8(11):1 5. doi:10.18203/2349 3291.ijcp20214071.
7. Wang R, Mihaicuta S, Tiotiu A, Corlateanu A, Ioan IC, Bikov A. Asthma and obstructive sleep apnoea in adults and children–an up to date review. Sleep Med Rev. 2022;61:101564. (Month not provided)
8. García Marcos L, Chiang CY, Asher MI, Marks GB, El Sony A, Masekela R, et al. Asthma management and control in children, adolescents, and adults in 25 countries: a Global Asthma Network Phase I cross sectional study. Lancet Glob Health. 2023 Feb;11(2):e218 e228. doi:10.1016/S2214 109X(22)00506 X.
9. Xu H, Tong L, Gao P, Hu Y, Wang H, Chen Z. Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: a meta analysis. PLoS One. 2021 Feb;16(2):e0237620. doi:10.1371/journal.pone.0237620.
10. Duan Y, Zhou H, Chen J. The effects of the atomization inhalation of budesonide, salbutamol, and ipratropium bromide on the T lymphocyte subset and inflammatory cytokine levels in children with asthmatic pneumonia. Am J Transl Res. 2021;13(9):10517 10526. (Month not provided)
11. Joiya SJ, ul Haq F, Khan MA, Ahmad Z. Comparison of salbutamol alone and salbutamol in combination with ipratropium bromide in treatment of acute asthma in children. Prof Med J. 2020 Jun;27(6):1103 1106. doi:10.29309/TPMJ/2020.27.06.3218.
12. Iramain R, Lopez Herce J, Coronel J, Spitters C, Guggiari J, Bogado N. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma. 2011 Mar;48(3):298 303. doi:10.3109/02770903.2011.555037.
13. Memon BN, Parkash A, Ahmed Khan KM, Gowa MA, Bai C. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. J Pak Med Assoc. 2016 Mar;66(3):243 246. (DOI not located)
14. Smith SR, Baty JD, Hodge III D. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med. 2002 Feb;9(2):99 104. doi:10.1111/j.1553 2712.2002.tb00223.x.
15. Arslan B, Çetin GP, Yilmaz İ. The role of long acting antimuscarinic agents in the treatment of asthma. J Aerosol Med Pulm Drug Deliv. 2023;36(4):189 209. doi:10.1089/jamp.2022.0059. (Month not provided)
16. Hodge MX, Henriquez AR, Kodavanti UP. Adrenergic and glucocorticoid receptors in the pulmonary health effects of air pollution. Toxics. 2021 Jun;9(6):132. doi:10.3390/toxics9060132.
17. Baker JG, Shaw DE. Asthma and COPD: a focus on β Agonists–past, present and future. Handb Exp Pharmacol. 2024;285:369 451. (Month not available)
18. Papi A, Chipps BE, Beasley R, Panettieri Jr RA, Israel E, Cooper M, et al. Albuterol–budesonide fixed dose combination rescue inhaler for asthma. N Engl J Med. 2022 Jun;386(22):2071 2083. doi:10.1056/NEJMoa2203163.
19. Rodrigo GJ, Castro Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta analysis. Thorax. 2005 Sep;60(9):740 746. doi:10.1136/thx.2005.040444.
20. Minhas S, Aslam S, Farooq MA, Anwar A, Zahoor F, Maqbool T, et al. Comparison of Salbutamol and Salbutamol with ipratropium bromide in children with exacerbation of asthma in terms of peak expiratory flow rate (PEFR). Prof Med J. 2021 Nov;28(11):1611 1615. doi:10.29309/TPMJ/2021.28.11.5904.
21. Khan A, Ahmad M. Comparison of salbutamol alone with salbutamol plus ipratropium bromide in the treatment of acute asthma in children. Khyber J Med Sci. 2016 Sep;9(3):391 394. (DOI not found)
22. Butt MA, Butt MA, Saleem S, Huda BT, Arif MM, Sahi SM. Peak expiratory flow rate with salbutamol plus ipratropium bromide versus salbutamol alone in acute asthma in children in Lahore, Pakistan: a randomized controlled trial. Gomal J Med Sci. 2022 Oct;20(4):167 171. doi:10.46903/gjms/20.04.1168.
23. Wyatt EL, Borland ML, Doyle SK, Geelhoed GC. Metered dose inhaler ipratropium bromide in moderate acute asthma in children: a single blinded randomised controlled trial. J Paediatr Child Health. 2015 Feb;51(2):192 198. doi:10.1111/jpc.12692.
24. Ahmad F, Akhtar S, Nafis S, Haider Z, Gul M, Hussain G, et al. Compare the efficacy of ipratropium bromide with salbutamol and salbutamol alone in recurrent wheezes in children with asthma presenting to LRH, Peshawar. Pak J Med Health Sci. 2023 Mar;17(03):357. doi:10.53350/pjmhs2023173357.
25. Bel EH. Severe asthma. Breathe. 2006 Jun;3(2):128 139. doi:10.1183/18106838.0302.128.
26. Abood HA, Al Musawi ZM, Hussein AM, Hameed RM. Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: a comparative study. clinical trials. J Pak Med Assoc. 2021 Dec;71(Suppl 9)(12):S29 S34.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
